Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Poziotinib for Patients With HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Mar 2022

Elamin Yasir Y, Robichaux Jacqulyne P, Carter Brett W, Altan Mehmet, Gibbons Don L, Fossella Frank V, Lam Vincent K, Patel Anisha B, Negrao Marcelo V, Le Xiuning, Mott Frank E, Zhang Jianjun, Feng Lei, Blumenschein George, Tsao Anne S, Heymach John V

Abstract excerpt

PURPOSE: Targeted therapies against non-small-cell lung cancer (NSCLC) harboring HER2 mutations remain an unmet need. In this study, we assessed the efficacy and safety of poziotinib in patients with HER2 exon 20 mutant advanced NSCLC in a single-arm, open-label, phase II study. PATIENTS AND METHODS: Patients with advanced HER2 exon 20 mutant NSCLC were enrolled to receive poziotinib at a dose of 16 mg/d for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Exons

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Follow-Up Studies

Share to Lung Neoplasms

Share to Prognosis

Share to Quinazolines

Share to Receptor, ErbB-2

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 34550757
DOI: 10.1200/JCO.21.01113
PMCID: PMC8887948

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Poziotinib for Patients With HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial.PMID 34550757Read ↗

Poziotinib in non-small-cell lung cancer patients with HER2 exon 20 mutations: A pooled analysis of randomized clinical trials.Semantic proximity Read ↗

Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4).Semantic proximity Read ↗

Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.Semantic proximity Read ↗

First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer in the Phase III EXCLAIM-2 TrialSemantic proximity Read ↗

FDA Approval Summary: Mobocertinib for Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.Semantic proximity Read ↗

Zongertinib in Previously Treated HER2 -Mutant Non–Small-Cell Lung CancerSemantic proximity Read ↗

Epidermal growth factor receptor tyrosine kinase inhibitor for the treatment of non-small cell lung cancer in the past 30 years (1997-2026).Semantic proximity Read ↗

First-Line Zongertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non–Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without AmivantamabSemantic proximity Read ↗

Very first real-world data on zongertinib use in non-small cell lung cancer patients with HER2 mutations: A brief report.Semantic proximity Read ↗

A real-world study of the efficacy and safety of furmonertinib for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations.Semantic proximity Read ↗

Real-world therapeutic strategies and survival outcomes in advanced HER2 -mutant non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.